Literature DB >> 4501130

Epinephrine binding to the catecholamine receptor and activation of the adenylate cyclase in erythrocyte membranes (hormone receptor- -adrenergic receptor-cyclic AMP-turkey).

M Schramm, H Feinstein, E Naim, E Lang, M Lasser.   

Abstract

Turkey erythrocyte membranes showed specific binding of [(3)H]epinephrine. The concentration of hormone required for half-maximal binding (30 muM) was the same as that required for half-maximal activation of the adenylate cyclase located in the same membrane preparation. The binding reaction at 37 degrees C reached completion during the first minute of incubation, which agrees well with the known rapidity of the biological response to catecholamines. Specific binding was abolished by heating the membranes 1 min at 100 degrees C. Chromatography of the bound (3)H, after its extraction from the membranes, indicated that the hormone had fully retained its chemical structure. Epinephrine binding was inhibited by the beta-adrenergic blocking agent propranolol, which also inhibited the activation of adenylate cyclase by the hormone. The specificity of phenethylamine derivatives in displacing [(3)H]epinephrine from the binding sites showed that a typical catecholamine receptor was responsible for the binding. Displacement of the bound hormone by analogs lacking the catechol group was more extensive at 37 degrees C than at 0 degrees C. Some of the analogs that displaced epinephrine from the binding site caused only a feeble activation of the adenylate cyclase, but were able to inhibit the activation of the enzyme by epinephrine. Thus, binding to a catecholamine receptor on a membrane preparation is an essential, but insufficient, condition to elicit a response.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4501130      PMCID: PMC426494          DOI: 10.1073/pnas.69.2.523

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Separation of catecholamines by paper chromatography.

Authors:  B WEISS; C V ROSSI
Journal:  Nature       Date:  1962-07-14       Impact factor: 49.962

2.  Adenyl cyclase. IV. The effects of neurohormones on the formation of adenosine 3',5'-phosphate by preparations from brain and other tissues.

Authors:  L M KLAINER; Y M CHI; S L FREIDBERG; T W RALL; E W SUTHERLAND
Journal:  J Biol Chem       Date:  1962-04       Impact factor: 5.157

3.  Adenyl cyclase. III. The effect of catecholamines and choline esters on the formation of adenosine 3',5'-phosphate by preparations from cardiac muscle and liver.

Authors:  F MURAD; Y M CHI; T W RALL; E W SUTHERLAND
Journal:  J Biol Chem       Date:  1962-04       Impact factor: 5.157

4.  Autoinhibition of acetylcholine binding to Torpedo electroplax; a possible molecular mechanism for desensitization.

Authors:  M E Eldefrawi; R D O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  1971-09       Impact factor: 11.205

5.  Insulin-receptor interactions in liver cell membranes.

Authors:  P Cuatrecasas; B Desbuquois; F Krug
Journal:  Biochem Biophys Res Commun       Date:  1971-07-16       Impact factor: 3.575

6.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. 3. Binding of glucagon: method of assay and specificity.

Authors:  M Rodbell; H M Krans; S L Pohl; L Birnbaumer
Journal:  J Biol Chem       Date:  1971-03-25       Impact factor: 5.157

7.  A fraction of the ventricular myocardium that has the specificity of the cardiac beta-adrenergic receptor.

Authors:  R J Lefkowitz; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

8.  Hormone action at the membrane level. II. The binding of epinephrine and glucagon to the rat liver plasma membrane.

Authors:  V Tomasi; S Koretz; T K Ray; J Dunnick; G V Marinetti
Journal:  Biochim Biophys Acta       Date:  1970-07-07

9.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. I. Properties.

Authors:  S L Pohl; L Birnbaumer; M Rodbell
Journal:  J Biol Chem       Date:  1971-03-25       Impact factor: 5.157

10.  Molecular biology of synaptic receptors.

Authors:  E De Robertis
Journal:  Science       Date:  1971-03-12       Impact factor: 47.728

View more
  8 in total

1.  Characterization of pharmacological receptors.

Authors:  E O Titus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Mode of action of cholera toxin: stabilization of catecholamine-sensitive adenylate cyclase in turkey erythrocytes.

Authors:  M Field
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

3.  Identification of the cardiac beta-adrenergic receptor protein: solubilization and purification by affinity chromatography.

Authors:  R J Lefkowitz; E Haber; D O'Hara
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

4.  Catecholamine binding to the beta-adrenergic receptor.

Authors:  R J Lefkowitz; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

5.  A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.

Authors:  Jillian G Baker
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

6.  The binding characteristics and number of beta-adrenergic receptors on the turkey erythrocyte.

Authors:  A Levitzki; D Atlas; M L Steer
Journal:  Proc Natl Acad Sci U S A       Date:  1974-07       Impact factor: 11.205

7.  Identification of cardiac beta-adrenergic receptors by (minus) [3H]alprenolol binding.

Authors:  R W Alexander; L T Williams; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

8.  The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor.

Authors:  Jillian G Baker; Richard G W Proudman; Christopher G Tate
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-06       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.